# An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

> **NCT02394834** · — · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 757 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- **DRUG:** oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

## Key facts

- **NCT ID:** NCT02394834
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05-29
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 757 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02394834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02394834, "An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02394834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*